Psoriatic arthritis. Reactive arthritis. Ankylosing Spondylitis,
ADEM, MOGAD, Polymyalgia Rheumatica.
Ms is usually diagnosed retrospective .
Htlv can cause transverse myelitis. And Human HTLV-1-Associated Myelopathy
ADEM, MOGAD, Polymyalgia Rheumatica.
Ms is usually diagnosed retrospective .
Htlv can cause transverse myelitis. And Human HTLV-1-Associated Myelopathy
November 3, 2026 at 7:37 AM
Psoriatic arthritis. Reactive arthritis. Ankylosing Spondylitis,
ADEM, MOGAD, Polymyalgia Rheumatica.
Ms is usually diagnosed retrospective .
Htlv can cause transverse myelitis. And Human HTLV-1-Associated Myelopathy
ADEM, MOGAD, Polymyalgia Rheumatica.
Ms is usually diagnosed retrospective .
Htlv can cause transverse myelitis. And Human HTLV-1-Associated Myelopathy
A new review article in @FrontNeurol summarizes evidence on #MOGAD treatment, focusing on treating attacks, preventing relapses, and managing symptoms.
TSF is proud to have supported open access fees.
Read the summary: www.sumairafoundation.org/summaries/tr...
TSF is proud to have supported open access fees.
Read the summary: www.sumairafoundation.org/summaries/tr...
November 2, 2026 at 1:53 PM
A new review article in @FrontNeurol summarizes evidence on #MOGAD treatment, focusing on treating attacks, preventing relapses, and managing symptoms.
TSF is proud to have supported open access fees.
Read the summary: www.sumairafoundation.org/summaries/tr...
TSF is proud to have supported open access fees.
Read the summary: www.sumairafoundation.org/summaries/tr...
Child neurology grand rounds this week falls on both an interview day AND Election Day, with “MOGAD: An Update,” by our own Dr. Lauren Krupp, MD, Nancy Glickenhaus Pier Professor of Pediatric Neuropsychiatry and Neurology and Division Director for Multiple Sclerosis at NYUGSoM:
November 3, 2026 at 5:24 PM
Child neurology grand rounds this week falls on both an interview day AND Election Day, with “MOGAD: An Update,” by our own Dr. Lauren Krupp, MD, Nancy Glickenhaus Pier Professor of Pediatric Neuropsychiatry and Neurology and Division Director for Multiple Sclerosis at NYUGSoM:
Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSD: The Role of Disease Activity in MOGAD. www.neurology.org/doi/10.1212/... #hvhebron #nimm
Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSD | Neurology
Background and ObjectivesMultiple sclerosis (MS), myelin oligodendrocyte glycoprotein antibody–associated disease
(MOGAD), and aquaporin-4 antibody–positive neuromyelitis optica spectrum disorder
(AQP...
www.neurology.org
October 27, 2026 at 11:24 AM
Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSD: The Role of Disease Activity in MOGAD. www.neurology.org/doi/10.1212/... #hvhebron #nimm
I do remember being told I have no signs of AS. Doesn't look like I've been tested for ADEM, MOGAD, or PR. My ESR and CRP used to be very high, like 44 at one point (supposed to be <5), but it's returned to normal since being on Mounjaro.
November 3, 2026 at 8:04 AM
I do remember being told I have no signs of AS. Doesn't look like I've been tested for ADEM, MOGAD, or PR. My ESR and CRP used to be very high, like 44 at one point (supposed to be <5), but it's returned to normal since being on Mounjaro.
New clinical trial
Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients Health
#ClinicalTrials #MultipleSclerosis #MSchat #Neurology
Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients Health
#ClinicalTrials #MultipleSclerosis #MSchat #Neurology
Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients Health
The goal of this observational study is to learn why some families have several members with multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), or MOG antibody-associated disease (MOGAD). These diseases happen when the immune system attacks the brain, opt...
brain-regeneration.com
October 28, 2026 at 12:40 PM
New clinical trial
Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients Health
#ClinicalTrials #MultipleSclerosis #MSchat #Neurology
Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients Health
#ClinicalTrials #MultipleSclerosis #MSchat #Neurology
Donem la benvinguda a la Dra. Maria Sepúlveda al Consell Assessor Mèdic i Científic de The MOG Project! 💗 La seva experiència en MOGAD, el diagnòstic i els tractaments emergents contribuirà a impulsar la recerca i millorar l’atenció arreu del món.
#sepulvedaboard/#sepulveda" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">mogproject.org/medical-advisory-board/#sepulveda
#sepulvedaboard/#sepulveda" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">mogproject.org/medical-advisory-board/#sepulveda
October 28, 2026 at 1:42 PM
Donem la benvinguda a la Dra. Maria Sepúlveda al Consell Assessor Mèdic i Científic de The MOG Project! 💗 La seva experiència en MOGAD, el diagnòstic i els tractaments emergents contribuirà a impulsar la recerca i millorar l’atenció arreu del món.
#sepulvedaboard/#sepulveda" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">mogproject.org/medical-advisory-board/#sepulveda
#sepulvedaboard/#sepulveda" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">mogproject.org/medical-advisory-board/#sepulveda
When your child has MOGAD, the whole family goes through it. 🩷 Drs. Brenda Banwell and Haiwen Chen of Johns Hopkins on behavior changes in kids and why parents' mental health matters: mogproject.org/behavior-changes-children-mogad/
More in our Family Bulletin: mogproject.org/family-newsletter
More in our Family Bulletin: mogproject.org/family-newsletter
October 26, 2026 at 4:01 PM
When your child has MOGAD, the whole family goes through it. 🩷 Drs. Brenda Banwell and Haiwen Chen of Johns Hopkins on behavior changes in kids and why parents' mental health matters: mogproject.org/behavior-changes-children-mogad/
More in our Family Bulletin: mogproject.org/family-newsletter
More in our Family Bulletin: mogproject.org/family-newsletter
👥 Bringing research closer to patients.
Patient Community Day at #MSToronto2026 brought patients and researchers together to explore MS, NMOSD and MOGAD, ask questions and share experiences.
The programme was available onsite and online, with translations in 50 languages. 💙
Patient Community Day at #MSToronto2026 brought patients and researchers together to explore MS, NMOSD and MOGAD, ask questions and share experiences.
The programme was available onsite and online, with translations in 50 languages. 💙
October 26, 2026 at 11:52 AM
👥 Bringing research closer to patients.
Patient Community Day at #MSToronto2026 brought patients and researchers together to explore MS, NMOSD and MOGAD, ask questions and share experiences.
The programme was available onsite and online, with translations in 50 languages. 💙
Patient Community Day at #MSToronto2026 brought patients and researchers together to explore MS, NMOSD and MOGAD, ask questions and share experiences.
The programme was available onsite and online, with translations in 50 languages. 💙
What a day in NYC! 🩷 Yesterday, Julia Lefelar joined SRNA at the SRNA NYC Walk, Run & Roll in Rockefeller Park. The walk helps send kids with rare neuroimmune conditions to SRNA's family camp in 2027, and The MOG Project was proud to donate. #MOGAD #RareDisease
October 25, 2026 at 3:00 PM
What a day in NYC! 🩷 Yesterday, Julia Lefelar joined SRNA at the SRNA NYC Walk, Run & Roll in Rockefeller Park. The walk helps send kids with rare neuroimmune conditions to SRNA's family camp in 2027, and The MOG Project was proud to donate. #MOGAD #RareDisease
#MSToronto2026 - Among patients with #MOGAD, treatment with #tocilizumab, compared with rituximab, resulted in near-complete relapse suppression and demonstrated less between-study heterogeneity.
https://bit.ly/3VZLoXc
https://bit.ly/3VZLoXc
Tocilizumab May Suppress MOGAD Relapses More Consistently Than Rituximab
Tocilizumab may offer more consistent relapse suppression than rituximab in MOGAD, though pooled estimates do not establish direct superiority.
www.neurologyadvisor.com
October 23, 2026 at 4:48 PM
#MSToronto2026 - Among patients with #MOGAD, treatment with #tocilizumab, compared with rituximab, resulted in near-complete relapse suppression and demonstrated less between-study heterogeneity.
https://bit.ly/3VZLoXc
https://bit.ly/3VZLoXc
The MOG Project team is in Toronto representing the MOGAD community at #ECTRIMS2026! 🩷🩵
Patient Day starts in just a few hours. Watch Julia Lefelar, our Executive Director & Co-founder, in the Lived Experience Q&A on Clinical Updates at 2:30 PM ET.
www.ectrimspatientcommunity.eu
Patient Day starts in just a few hours. Watch Julia Lefelar, our Executive Director & Co-founder, in the Lived Experience Q&A on Clinical Updates at 2:30 PM ET.
www.ectrimspatientcommunity.eu
October 23, 2026 at 12:51 PM
The MOG Project team is in Toronto representing the MOGAD community at #ECTRIMS2026! 🩷🩵
Patient Day starts in just a few hours. Watch Julia Lefelar, our Executive Director & Co-founder, in the Lived Experience Q&A on Clinical Updates at 2:30 PM ET.
www.ectrimspatientcommunity.eu
Patient Day starts in just a few hours. Watch Julia Lefelar, our Executive Director & Co-founder, in the Lived Experience Q&A on Clinical Updates at 2:30 PM ET.
www.ectrimspatientcommunity.eu
Present at the interesting session: MOGAD Novelties in Disease Course and Treatment at #MSToronto2026
October 22, 2026 at 6:51 PM
Present at the interesting session: MOGAD Novelties in Disease Course and Treatment at #MSToronto2026
Thank you, ECTRIMS, for having The MOG Project at #ECTRIMS2026! 🩷🩵
Patient Day drew ~4,000 registrants and featured the first-ever dedicated MOGAD and NMOSD panels. We're proud of Julia Lefelar for sharing her lived experience!
Did you tune in? Share your takeaway below!
Patient Day drew ~4,000 registrants and featured the first-ever dedicated MOGAD and NMOSD panels. We're proud of Julia Lefelar for sharing her lived experience!
Did you tune in? Share your takeaway below!
October 23, 2026 at 9:45 PM
Thank you, ECTRIMS, for having The MOG Project at #ECTRIMS2026! 🩷🩵
Patient Day drew ~4,000 registrants and featured the first-ever dedicated MOGAD and NMOSD panels. We're proud of Julia Lefelar for sharing her lived experience!
Did you tune in? Share your takeaway below!
Patient Day drew ~4,000 registrants and featured the first-ever dedicated MOGAD and NMOSD panels. We're proud of Julia Lefelar for sharing her lived experience!
Did you tune in? Share your takeaway below!
Thank you to everyone who has already shared their story in the IMPACT Study. 🩷🩵
Haven’t yet? It’s still open for ages 12–20 with MOGAD and parents or guardians of anyone 0–20 with MOGAD. Anonymous, about 20–30 minutes.
redcap.link/impact-survey
#MOGAD
Haven’t yet? It’s still open for ages 12–20 with MOGAD and parents or guardians of anyone 0–20 with MOGAD. Anonymous, about 20–30 minutes.
redcap.link/impact-survey
#MOGAD
October 22, 2026 at 3:09 AM
Thank you to everyone who has already shared their story in the IMPACT Study. 🩷🩵
Haven’t yet? It’s still open for ages 12–20 with MOGAD and parents or guardians of anyone 0–20 with MOGAD. Anonymous, about 20–30 minutes.
redcap.link/impact-survey
#MOGAD
Haven’t yet? It’s still open for ages 12–20 with MOGAD and parents or guardians of anyone 0–20 with MOGAD. Anonymous, about 20–30 minutes.
redcap.link/impact-survey
#MOGAD
Day 2 at #MSToronto2026: predict earlier, diagnose earlier, personalise better. 🧠
From biomarkers and prodromal phases in NMOSD to imaging in MOGAD.
The key: real-world data and patient-reported outcomes must move with it. Patient perspectives belong at the heart of progress.
From biomarkers and prodromal phases in NMOSD to imaging in MOGAD.
The key: real-world data and patient-reported outcomes must move with it. Patient perspectives belong at the heart of progress.
October 22, 2026 at 9:01 PM
Day 2 at #MSToronto2026: predict earlier, diagnose earlier, personalise better. 🧠
From biomarkers and prodromal phases in NMOSD to imaging in MOGAD.
The key: real-world data and patient-reported outcomes must move with it. Patient perspectives belong at the heart of progress.
From biomarkers and prodromal phases in NMOSD to imaging in MOGAD.
The key: real-world data and patient-reported outcomes must move with it. Patient perspectives belong at the heart of progress.
Not every disability is visible. 💗 MOG antibody disease (MOGAD) can cause symptoms others may not recognize. This Invisible Disabilities Week, let’s listen without assumptions, lead with empathy, and remember that looking well doesn’t always mean feeling well.
mogproject.org/symptoms
mogproject.org/symptoms
October 21, 2026 at 1:31 PM
Not every disability is visible. 💗 MOG antibody disease (MOGAD) can cause symptoms others may not recognize. This Invisible Disabilities Week, let’s listen without assumptions, lead with empathy, and remember that looking well doesn’t always mean feeling well.
mogproject.org/symptoms
mogproject.org/symptoms
Movement is one of the most powerful tools for brain health.
Join our webinar on practical strategies for staying active with MS, NMOSD or MOGAD, with Prof. Philipp Zimmer, @tu-dortmund.de and patient advocate, Janneke Benders.
📅 Thu 29 Oct, 16:00–17:00 CET
👉 Register: bit.ly/4i3b9NL
Join our webinar on practical strategies for staying active with MS, NMOSD or MOGAD, with Prof. Philipp Zimmer, @tu-dortmund.de and patient advocate, Janneke Benders.
📅 Thu 29 Oct, 16:00–17:00 CET
👉 Register: bit.ly/4i3b9NL
October 20, 2026 at 2:45 PM
Movement is one of the most powerful tools for brain health.
Join our webinar on practical strategies for staying active with MS, NMOSD or MOGAD, with Prof. Philipp Zimmer, @tu-dortmund.de and patient advocate, Janneke Benders.
📅 Thu 29 Oct, 16:00–17:00 CET
👉 Register: bit.ly/4i3b9NL
Join our webinar on practical strategies for staying active with MS, NMOSD or MOGAD, with Prof. Philipp Zimmer, @tu-dortmund.de and patient advocate, Janneke Benders.
📅 Thu 29 Oct, 16:00–17:00 CET
👉 Register: bit.ly/4i3b9NL
Welcome Dr. Haiwen Chen to our Medical & Scientific Advisory Council!
A pediatric neuroimmunologist at Johns Hopkins, Dr. Chen studies MOGAD diagnosis and treatment and investigates how myelin-producing cells influence neuronal communication.
#chenard/#chen" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://mogproject.org/medical-advisory-board/#chen
A pediatric neuroimmunologist at Johns Hopkins, Dr. Chen studies MOGAD diagnosis and treatment and investigates how myelin-producing cells influence neuronal communication.
#chenard/#chen" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://mogproject.org/medical-advisory-board/#chen
October 20, 2026 at 2:30 AM
Welcome Dr. Haiwen Chen to our Medical & Scientific Advisory Council!
A pediatric neuroimmunologist at Johns Hopkins, Dr. Chen studies MOGAD diagnosis and treatment and investigates how myelin-producing cells influence neuronal communication.
#chenard/#chen" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://mogproject.org/medical-advisory-board/#chen
A pediatric neuroimmunologist at Johns Hopkins, Dr. Chen studies MOGAD diagnosis and treatment and investigates how myelin-producing cells influence neuronal communication.
#chenard/#chen" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://mogproject.org/medical-advisory-board/#chen
🧠 Satralizumab (Enspryng) reduced relapse risk by 68% vs placebo in the phase 3 METEOROID trial in relapsing MOGAD
📊 At 48 weeks, 87.3% of patients receiving satralizumab remained relapse-free vs 66.5% with placebo
🔬 Findings from #CNS2026: www.neurologylive.com/view/satrali...
#MOGAD #Neurology
📊 At 48 weeks, 87.3% of patients receiving satralizumab remained relapse-free vs 66.5% with placebo
🔬 Findings from #CNS2026: www.neurologylive.com/view/satrali...
#MOGAD #Neurology
Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.
www.neurologylive.com
October 16, 2026 at 1:03 PM
🧠 Satralizumab (Enspryng) reduced relapse risk by 68% vs placebo in the phase 3 METEOROID trial in relapsing MOGAD
📊 At 48 weeks, 87.3% of patients receiving satralizumab remained relapse-free vs 66.5% with placebo
🔬 Findings from #CNS2026: www.neurologylive.com/view/satrali...
#MOGAD #Neurology
📊 At 48 weeks, 87.3% of patients receiving satralizumab remained relapse-free vs 66.5% with placebo
🔬 Findings from #CNS2026: www.neurologylive.com/view/satrali...
#MOGAD #Neurology
Moving more is one of the easiest ways to support brain health, but with MS, NMOSD or MOGAD, fatigue, heat and relapse worries can get in the way.
Prof. Philipp Zimmer, @tu-dortmund.de & advocate Janneke Benders on how to start and keep going.
13 Oct · 16:00 CEST
Register bit.ly/4i3b9NL
Prof. Philipp Zimmer, @tu-dortmund.de & advocate Janneke Benders on how to start and keep going.
13 Oct · 16:00 CEST
Register bit.ly/4i3b9NL
October 16, 2026 at 11:00 AM
Moving more is one of the easiest ways to support brain health, but with MS, NMOSD or MOGAD, fatigue, heat and relapse worries can get in the way.
Prof. Philipp Zimmer, @tu-dortmund.de & advocate Janneke Benders on how to start and keep going.
13 Oct · 16:00 CEST
Register bit.ly/4i3b9NL
Prof. Philipp Zimmer, @tu-dortmund.de & advocate Janneke Benders on how to start and keep going.
13 Oct · 16:00 CEST
Register bit.ly/4i3b9NL
📢 Reminder: One week left until Patient Community Day – which will be LIVE in 50+ languages! Join us for this free event, where experts break down valuable insights in MS, NMOSD & MOGAD research.
🗓️ 23 Oct | 15:00 EDT
Sign up ➡️ www.ectrimspatientcommunity.eu/registration
🗓️ 23 Oct | 15:00 EDT
Sign up ➡️ www.ectrimspatientcommunity.eu/registration
October 15, 2026 at 12:01 PM
📢 Reminder: One week left until Patient Community Day – which will be LIVE in 50+ languages! Join us for this free event, where experts break down valuable insights in MS, NMOSD & MOGAD research.
🗓️ 23 Oct | 15:00 EDT
Sign up ➡️ www.ectrimspatientcommunity.eu/registration
🗓️ 23 Oct | 15:00 EDT
Sign up ➡️ www.ectrimspatientcommunity.eu/registration
LIVE in 1️⃣ week! Join us at Patient Community Day on 23 Oct from 15:00-18:00 EDT, where experts simplify the latest updates in MS, MOGAD & NMOSD research. This is a free event available in 50+ languages. #ECTRIMS4me #ProudSupporters
Sign up here: https://www.ectrimspatientcommunity.eu/registration
Sign up here: https://www.ectrimspatientcommunity.eu/registration
Registration
Register for access to the free recorded livestream from Patient Community Day, which was held on 26 September 2025 in Barcelona, Spain. Learn from top neurological experts about the latest MS research and treatments.
www.ectrimspatientcommunity.eu
October 16, 2026 at 1:21 AM
LIVE in 1️⃣ week! Join us at Patient Community Day on 23 Oct from 15:00-18:00 EDT, where experts simplify the latest updates in MS, MOGAD & NMOSD research. This is a free event available in 50+ languages. #ECTRIMS4me #ProudSupporters
Sign up here: https://www.ectrimspatientcommunity.eu/registration
Sign up here: https://www.ectrimspatientcommunity.eu/registration